Heart Failure – BEAT HF 360043-001

Location: Las Vegas

Stay: None

Gender: Male/Female

Ages: 21+

Smokers Allowed: Yes

Study Overview:

The purpose of this clinical study is to determine whether Baroreflex Activation Therapy™ with the Barostim neo system is safe and reduces the risk of cardiovascular mortality and heart failure events in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy.

Enroll In This Study